Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors

Rationale: Prostate cancer (PCa) recurrences after surgery frequently occur. To improve the outcome after surgical resection of the tumor, the theranostic multimodal anti-PSMA targeting agent 111 In-DTPA-D2B-IRDye700DX was developed and characterized for both pre-and intra-operative tumor localization and eradication of (residual) tumor tissue by PSMA-targeted photodynamic therapy (tPDT), which is a highly selective cancer treatment based on targeting molecules conjugated to photosensitizers that can induce cell destruction upon exposure to near-infrared (NIR) light. Methods: The anti-PSMA monoclonal antibody D2B was conjugated with IRDye700DX and DTPA and subsequently radiolabeled with 111 In. To determine the optimal dose and time point for tPDT, BALB/c nude mice with PSMA-expressing (PSMA + ) s.c. LS174T-PSMA xenografts received the conjugate (24-240 g/mouse) intravenously (8 MBq/mouse) followed by SPECT/CT, near-infrared fluorescence imaging, and ex vivo biodistribution at 24, 48, 72 and 168 h p.i. Tumor growth of LS174T-PSMA xenografts and overall survival of mice treated with 1-3 times of NIR light irradiation (50, 100, 150 J/cm 2 ) 24 h after injection of 80 g of DTPA-D2B-IRDye700DX was compared to control conditions. Results: Highest specific tumor uptake was observed at conjugate doses of 80 g/mouse. Biodistribution revealed no significant difference in tumor uptake in mice at 24, 48, 72 and 168 h p.i. PSMA + tumors were clearly visualized with both SPECT/CT and NIR fluorescence imaging. Overall survival in mice treated with 80 g of DTPA-D2B-IRDye700DX and 1x 150 J/cm 2 of NIR light at 24 h p.i. was significantly improved compared to the control group receiving neither conjugate nor NIR light (73 days vs. 16 days, respectively, p=0.0453). Treatment with 3x 150 J/cm 2 resulted in significantly prolonged survival compared to treatment with 3x 100 J/cm 2 (p = 0.0067) and 3x 50 J/cm 2 (p = 0.0338). Principal conclusions: 111 In-DTPA-D2B-IRDye700DX can be used for pre-and intra-operative detection of PSMA + tumors with radionuclide and NIR fluorescence imaging and PSMA-targeted PDT. PSMA-tPDT using this multimodal agent resulted in significant prolongation of survival and shows great potential for treatment of (metastasized) prostate cancer.